COL9A2

Across TCGA pan-cancer cohorts, COL9A2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated COL9A2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher COL9A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL9A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

GBM, HNSC, and LSCC are the cancer types where COL9A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.234	0.475	.016	6	view →
HNSC	OS	Tertile	All	1.000	0.785	.018	1	view →
LSCC	DFS	Median	II,III,IV	1.000	0.482	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

COL9A2–GBM (DFS)

Open the GBM breakdown →